Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...

Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal ...

Phase III data for dapirolizumab pegol presented at the 2025 American College of Rheumatology showed quality-of-life benefits ...

The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, ...

BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...

Executives from Eli Lilly, Merck and other companies foresee the FDA's new onshoring proposal being anything from a bureaucratic waste of time to a transformative program that will eliminate ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

New interim data from a Phase III trial puts the company on track to file for FDA approval next year in an indication that ...

Lynkuet is the first FDA-approved therapy that blocks both the neurokinin 1 and neurokinin 3 receptors to treat hot flashes.

The takeover of its competitor, announced Sunday, could also bring some attention to Dyne Therapeutics, which has a similar ...

Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...